Disease-State Whole Blood

GMP Whole Blood for Clinical trials, gene and cell therapy
Categories: ,

Disease-State Whole Blood provides researchers with access to peripheral blood collected from donors with relevant medical conditions for biomarker research, assay development, immune profiling, diagnostic research, drug development, and translational studies.

CGT Global can support disease-state whole blood projects using current inventory or prospective donor sourcing depending on the condition, donor criteria, collection volume, and study requirements.

  • Whole blood from selected disease-state donor populations
  • Fresh or cryopreserved options depending on product availability
  • Multiple anticoagulant and collection tube options
  • Custom donor inclusion and exclusion criteria can be evaluated
  • Recallable donors may support repeat or longitudinal collections
  • Healthy donor controls may also be available for comparative studies
Add to quote

The CGT Global Difference 

Learn More

Since our founding in 2010, CGT Global has pursued our mission to transform healthcare as we accelerate cell and gene therapy research and clinical trials, streamline the commercialization of new treatments, and map the last mile to patient access to these life-changing remedies.  By innovating each stage in the cycle; development, commercialization, and delivery, we reduce the overall cost of the care and multiply access points so that millions can receive cutting edge, life-saving gene and cell therapies.

CGT Global - Landing Page Desktop Prototype

Description

CGT Global provides disease-state whole blood collected from qualified, characterized donors for research use. Available donor populations may include individuals with autoimmune, neurological, metabolic, oncological, allergic, and other medical conditions.

Whole blood can be collected according to project-specific requirements, including requested collection volumes, anticoagulants, donor demographics, disease characteristics, medications, and processing timelines.

Key features:

• Fresh, ethically collected human whole blood
• Characterized disease-state donors
• Custom collection specifications
• Donor demographic and clinical information when available
• Access to recallable donors for longitudinal research
• Nationwide collection capabilities through CGT Global’s donor network

Availability varies by diagnosis and study requirements. Contact our team to review current inventory or discuss a prospective custom collection.

For research use only. Not for diagnostic or therapeutic use.

Related products